In this paper by King and colleagues (BMJ 2021;373:n1014, doi:10.1136/bmj.n1014, published 12 May 2021), the participants from the Heart of England NHS Foundation Trust were omitted […]
Preliminary RECOVERY trial results find a monoclonal antibody (MAB) drug by Regeneron reduces the risk of death in a subset of patients with severe COVID-19.